Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Datatrak widens pact with NTT DATA
With this extension, NTT DATA will continue to sell Datatrak eClinical and Enterprise Transfer services within the Japanese market. Moreover, Datatrak has decided to extend its product’s capabilities
With this extension, NTT DATA will continue to sell Datatrak eClinical and Enterprise Transfer services within the Japanese market. Moreover, Datatrak has decided to extend its product’s capabilities
Soliris (eculizumab) is indicated as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Alexion plans to launch the drug for the treatment of aHUS in the
The contract aims to refine, analyze and synthesize the active molecules derived from Health Enhancement Products’ proprietary algal extracts. The active molecules were the focus of the company’s
Patents currently granted cover Europe, the USA, Canada, Japan and India, with more patents in other countries being filed. The portable system has been developed for the treatment
With this expansion, the companies expect to develop and commercialize the HAE drug in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea. Under their
Initially, the company plans to roll out approximately 10-12 eye care pharma products in the metro cities of India by end of July, Pharmabizz reported. Bausch & Lomb‘s
The new patent entitled, ‘Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders,’ covers methods of utilizing QLT091001 to treat diseases linked with
Glysom is made from glycine, an amino acid that occurs naturally in the body. It is particularly effective in promoting the deep, non-REM sleep crucial to feeling refreshed
Donepezil Hydrochloride tablets are indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer’s type and fall under the central nervous system (CNS) therapeutic segment.
The orphan drugs status will allow the company to market its recombinant factor VIIa fused with albumin in Europe for a span of 10 years if the product